NIKKEI 225
38,677.12 -269.81 (-0.69%) HANG SENG
19,220.62 -415.60 (-2.12%) CRUDE OIL
79.06 -0.20 (-0.25%) GOLD FUTURES
2,425.30 -0.60 (-0.02%) DOW
39,872.99 +66.22 (+0.17%) Bitcoin GBP
55,179.98 -781.08 (-1.40%)
Stereotaxis, Inc. (STXS)
| Previous close | 2.0900 |
| Open | 2.0600 |
| Bid | 2.0800 x 800 |
| Ask | 2.1000 x 1300 |
| Day's range | 2.0600 - 2.1200 |
| 52-week range | 1.3300 - 3.2900 |
| Volume | |
| Avg. volume | 325,919 |
| Market cap | 174.377M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Stereotaxis Invited by Africa Heart Rhythm Association to Present its Innovative Robotic Solution to Expand High-Quality Therapy in Underserved Regions of Africa
ST. LOUIS, May 15, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has been invited to present at HRS Africa Summit 2024, scheduled to take place during Heart Rhythm Society Scientific Sessions this week in Boston, Massachusetts. Stereotaxis will present an innovative proposal leveraging advanced robotic technology and telerobotic presence to sustainably offer high-qualit
- GlobeNewswire
Stereotaxis Reports 2024 First Quarter Financial Results
ST. LOUIS, May 13, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the first quarter ended March 31, 2024. “Stereotaxis is driving continued commercial, technological, and strategic progress,” said David Fischel, Chairman and CEO. “We are pleased to report revenue growth in the first quarter and an increase in system backlog with two Genesis systems orders si
- GlobeNewswire
Stereotaxis Announces Definitive Agreement to Acquire Access Point Technologies
ST. LOUIS, May 13, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has entered into a definitive share purchase agreement under which Stereotaxis will acquire Access Point Technologies EP (APT), a privately-held Minnesota-based developer of innovative electrophysiology catheters. “Acquiring APT provides Stereotaxis with high-quality catheter development and manufacturing
